| abstract |
PURPOSE: To obtain a tumor-suppressing agent having remarkable effect especially to myelogenetic leukemia, by using a vitamin D derivative having OH group at the 1α-position as an active component. n CONSTITUTION: The objective agent contains a vitamin D derivative having OH group at the 1α-position (e.g. 1α-hydroxyvitamin D 3 , 1α,25-dihydroxyvitamin D 3 , 1α,24-dihydroxyvitamin D 3 , etc.) as an active component. The 1α-hydroxyvitamin D 3 has tumor-suppressing activity, i.e. redifferentiation of leukemia cell caused by the differentiation or dedifferentiation of cells. The agent is effective against the tumors such as myelo proliferative disorder, true plethora, leukemoid, leukemia, etc. Since the purpose can be achieved by an extremely small amount of administration, i.e. the blood concentration of 20W400pg/m, the agent is preferably administered in the form of a soft capsule. n COPYRIGHT: (C)1982,JPO&Japio |